Stock NOV NOV INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NOV Inc.

Equities

NOV

US62955J1034

Real-time Estimate Cboe BZX
Other stock markets
 03:03:30 2024-04-23 pm EDT 		5-day change 1st Jan Change
18.76 USD +0.89% Intraday chart for NOV Inc. -0.56% -7.52%
Apr. 18 Morgan Stanley Raises Price Target on NOV to $25 From $24 on Removal of 'Saudi Risk Premium,' Keeps Overweight Rating MT
Apr. 09 Arcosa Closes $180 Million Acquisition of Ameron Pole Products MT

Evolution of the average Target Price on NOV Inc.

Price target over the last 5 years

History of analyst recommendation changes

e816e4ace.iFihQGDRAYNog4Trjw2JWrJaA1CK0hOWh4FoGceebUk.xRHKJQ-cUPkY9_Cp6VikEYQySmPa_1j_2OQxaLauLh_SCeghCalH9CfJ1Q~56d2c2d3cddfa6c256c777560cf57f80

Analyst Recommendations on NOV Inc.

Morgan Stanley Raises Price Target on NOV to $25 From $24 on Removal of 'Saudi Risk Premium,' Keeps Overweight Rating MT
Piper Sandler Adjusts NOV's Price Target to $22 From $25, Keeps Neutral Rating MT
Raymond James Adjusts Price Target on NOV to $25 From $28, Maintains Outperform Rating MT
TD Cowen Adjusts Price Target on NOV to $29 From $28, Maintains Outperform Rating MT
JPMorgan Upgrades NOV to Overweight From Neutral, Price Target at $25 MT
Goldman Sachs Raises Price Target on NOV to $19 From $18, Maintains Sell Rating MT
Raymond James Adjusts Price Target on NOV to $29 From $28, Maintains Outperform Rating MT
RBC Lifts Price Target on NOV Inc. to $24 From $23, Keeps Sector Perform Rating MT
Morgan Stanley Raises Price Target on NOV to $25 From $24, Keeps Overweight Rating MT
BofA Securities Adjusts Price Target on NOV to $24 From $21, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on NOV to $18 From $16, Maintains Sell Rating MT
Piper Sandler Adjusts Price Target on NOV to $20 From $22, Maintains Neutral Rating MT
JPMorgan Raises Price Target on NOV to $22 From $20, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on NOV to $24 From $22, Maintains Overweight Rating MT
Citigroup Adjusts NOV's Price Target to $26 From $21, Keeps Buy Rating MT
Raymond James Adjusts Price Target on NOV to $28 From $27, Maintains Outperform Rating MT
RBC Lifts Price Target on NOV to $23 From $22, Keeps Sector Perform Rating MT
Citigroup Trims NOV's Price Target to $21 From $22, Keeps Buy Rating MT
Capital One Reinstates NOV With Equalweight Rating, $20 Price Target MT
Raymond James Adjusts Price Target on NOV to $27 From $29, Maintains Outperform Rating MT
RBC Cuts Price Target on NOV to $22 From $25, Keeps Sector Perform Rating MT
Goldman Sachs Adjusts Price Target on NOV to $16 From $17, Maintains Sell Rating MT
Goldman Sachs Trims Price Target on NOV to $17 From $18, Maintains Sell Rating MT
Piper Sandler Adjusts NOV's Price Target to $21 From $22, Keeps Neutral Rating MT
Barclays Adjusts Price Target on NOV to $20 From $25, Keeps Equalweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
18.59 USD
Average target price
23.75 USD
Spread / Average Target
+27.76%
High Price Target
31 USD
Spread / Highest target
+66.76%
Low Price Target
17 USD
Spread / Lowest Target
-8.55%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NOV Inc.

Morgan Stanley
Piper Sandler
Raymond James
TD Cowen
JPMorgan Chase
Goldman Sachs
RBC Capital Markets
BofA Securities
Citigroup
Capital One Securities
Barclays
Cowen
Susquehanna
Benchmark Company
Wells Fargo Securities
Stifel Nicolaus
UBS
Coker Palmer Institutional
ATB Capital
BMO Capital
Seaport Global Securities

Ratings for NOV Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NOV Stock
  4. Consensus NOV Inc.